Peking Union Medical College Hospital Licenses Novel IPMN Mouse Model Technology for RMB 100,000

Recently, Peking Union Medical College Hospital, in accordance with the provisions of the “Administrative Measures for Promoting the Transformation of Scientific and Technological Achievements at Peking Union Medical College Hospital,” intends to“Preparation Method and Application of Mouse Models of Intraductal Papillary Mucinous Neoplasm of the Pancreas and Their Tumor Cells”Public Notice on the Transformation of Scientific and Technological Achievements. The hospital intends to transfer the rights to apply for a patent for this technological achievement to Beijing VTD Biotechnology Co., Ltd. through the assignment of patent application rights, with a proposed transaction price of RMB¥100,000. The individuals who completed this achievement transformation includeCui Ming and His Team。

The Assignee of the Patent TechnologyBeijing VTD Biotechnology Co., Ltd., specializing in the breeding of laboratory animals and the development of genetically modified animal models. It is equipped with facilities such as microinjection systems and ABSL-2 laboratories, and has established laboratory animal bases in Beijing, Hebei, and Jiangsu. Founded with support from the National 863 Program, the company focuses on the development of animal models for human diseases. It has developed NPG immunodeficient mice, humanized immune system models, and liver-repopulated models, which are applied in tumor immunotherapy and HBV drug research. The ES cell bank it established covers approximately 2,000 targeted cell lines, and its technical platforms include hepatocyte transplantation and hematopoietic cell transplantation. The 2024 spot inspection results showed that the NPG mice and FRG rats provided by the company both met the national SPF-grade standards. Its branch offices cover regions including Taiwan, China, Japan, and South Korea.

The patent proposed for transfer discloses a mouse model of intraductal papillary mucinous neoplasm (IPMN) of the pancreas, along with methods for its preparation and applications involving tumor cells. Specifically, it provides a method for constructing KPPS mice through crossbreeding parent mice with specific genotypes and successfully obtaining IPMN model mice using an inducer. This model can fully simulate the pathological progression of IPMN, providing a crucial experimental tool for in-depth research into its pathogenesis and development mechanisms, drug screening, and the development of new therapeutic strategies.

Intraductal Papillary Mucinous Neoplasm (IPMN) is one of the most common pancreatic cystic neoplasms. It is medically defined as a precursor lesion to pancreatic cancer, indicating that it carries the risk of progressing to malignant pancreatic cancer. The characteristic pathological feature of this tumor is the presence of papillary projections with branching structures growing on the walls of dilated pancreatic ducts. These projections are lined by neoplastic epithelial cells that produce and secrete large amounts of mucin. Mucin is a mucus-like substance that can accumulate and fill the lumen of the pancreatic ducts involved by the tumor.

At the molecular level, the initiation and progression of intraductal papillary mucinous neoplasm (IPMN) are accompanied by a series of specific genetic mutations. Mutations in genes such as KRAS and GNAS are considered early events driving tumor initiation. As the lesion progresses from benign to malignant, additional mutations in genes associated with malignant progression, such as TP53 and CDKN2A, further accumulate.

To gain a deeper understanding of how these genetic mutations lead to disease, scientists rely on genetically engineered mouse models. By simulating human genetic mutations in animals, these models enable the recapitulation of the entire process of tumorigenesis—from initiation to progression—within an intact biological system and immune microenvironment.

Among the numerous research models for pancreatic cancer, the KPPC mouse model has been widely used. It is genetically engineered to simultaneously carry the oncogenic Kras mutation and a deletion of the tumor suppressor gene Trp53.

However, the model usedCre Tool (Pdx1-CreER)Its expression is not limited to pancreatic ductal cells but is active in various pancreatic cell types. This “promiscuous” expression pattern results in tumors that do not specifically originate from the ducts, making it difficult to accurately model IPMN and its associated invasive carcinomas that arise purely from ductal cell evolution.

To establish more accurate models, researchers have turned their attention toSox9 GeneThis gene exhibits a specific expression pattern in pancreatic ductal cells of adult mice. By utilizing the Sox9 promoter to drive the CreER system, genetically engineered mouse models can be constructed for targeted genetic manipulation specifically in ductal cells. This provides a critical genetic platform for establishing IPMN models of ductal cell origin. However, studies have shown that activating oncogenic Kras mutations solely in ductal cells is insufficient to induce IPMN formation, indicating the need for synergistic effects from additional genetic events.

For example, studies have attempted to specifically knock out the Brg1 gene in ductal cells while inducing Kras mutations. This approach successfully induced IPMN-like precancerous lesions. However, the observation period for this model was short, with related studies tracking mice only up to 6 weeks of age, failing to fully capture the entire progression of the lesions to advanced stages.

Another study employed a strategy involving the activation of Kras mutations in ductal cells combined with Pten gene knockout. This combination successfully induced IPMN-like lesions, which ultimately progressed to invasive carcinoma. However, this model has a significant drawback: tumor progression is extremely slow. Mice must be aged 6 to 14 months before obvious tumor formation can be observed, substantially increasing the time and resource costs of the research.

Therefore, the development of an animal model capable of rapidly and specifically recapitulating the complete progression cycle of human intraductal papillary mucinous neoplasm (IPMN) has become a critical unmet need in this research field.

Therefore, to address the aforementioned research bottlenecks—namely, the limitations of existing models in cell-of-origin specificity and efficiency in simulating the complete pathological process—it is particularly urgent to develop an animal model capable of recapitulating the entire spectrum of human IPMN initiation and progression more rapidly and accurately.

The KPPS mouse model established in this patent has its core advantage inThrough precise genetic design,Fundamentally addresses the limitations of existing IPMN models in terms of cellular targeting specificity and the integrity of pathological processes.

This model innovatively adoptsSox9-CreER Tool MiceAs the driving engine for genetic manipulation. The Sox9 gene promoter exhibits strict specificity for pancreatic ductal cells, meaning that Cre recombinase expression driven by it is confined exclusively to ductal cells. This ensures that subsequent gene editing events occur precisely within the target cell population, enabling rigorous control over the cellular origin of tumors and effectively circumventing the issue of cellular heterogeneity associated with previously used pan-pancreatic Cre tools (such as Pdx1-CreER).

In terms of the combination of genetic events, this model simultaneously introduces the two most critical gene mutations found in human IPMN:Activated Oncogene KrasG12D and Inactivated Tumor Suppressor Gene Trp53. These two mutations were pre-engineered into the mouse genome using a sophisticated “conditional” gene targeting technique.

Specifically, a “switch” consisting of loxP sites flanking a stop sequence (LSL) is inserted upstream of the mutant KrasG12D gene, keeping it silent under normal conditions; similarly, key segments of the Trp53 gene are “flanked” by two loxP sites. Upon administration of the exogenous inducer tamoxifen to mice, the activated Cre recombinase precisely recognizes and cleaves these loxP sites.

This process is akin to unlocking a genetic lock: on one hand, it removes the stop signal upstream of KrasG12D, leading to its constitutive expression and driving abnormal cell proliferation; on the other hand, it excises critical segments of the Trp53 gene, resulting in loss of function and compromising the cellular surveillance mechanism for genomic stability. These two “double hits,” synchronously triggered within ductal cells, robustly and specifically initiate the tumorigenic program.

This design brings revolutionary modeling efficiency. Experimental data show that, after tamoxifen induction, KPPS mice can stably form within just 4 weeksLow-grade IPMN LesionMore importantly, the model successfully recapitulated the complete and continuous pathological progression from low-grade IPMN to high-grade IPMN, and ultimately to IPMN-associated invasive carcinoma, with the entire disease course completed within approximately 24 weeks.

Compared with previous models that required 6 to 14 months to observe advanced lesions, this approach significantly shortens the research cycle, providing scientists with an unprecedentedly efficient platform for dynamically studying the full spectrum of biological mechanisms underlying IPMN progression within a controllable time window.

Furthermore, the advanced nature of this model is also reflected in its high reproducibility and translatability. The tumor tissues successfully established from this modelKPPS Cell Line, maintained robust proliferative capacity and epithelial cell characteristics in vitro, providing a stable resource for high-throughput exploration of molecular mechanisms and drug sensitivity testing at the cellular level.

Further transplantation of KPPS cells into immunocompetent mice rapidly leads to the formation of subcutaneous tumors, demonstrating the strong tumorigenicity of these tumor cells and establishing a convenient preclinical evaluation system for assessing the efficacy of novel therapies, such as immunotherapy and targeted drugs.

Therefore, the KPPS model is not merely a basic research tool, but also a bridge connecting mechanistic discovery with therapeutic development, holding immeasurable application value in exploring the etiology of IPMN, identifying biomarkers, and developing innovative treatment strategies.

Therefore, in view of the widespread limitations of existing IPMN animal modelsThe protracted course of tumorigenesis, limited efficiency of malignant transformation, and the difficulty in fully recapitulating the natural history of the disease.These Three Core Bottlenecks,Develop an experimental model capable of accurately and efficiently recapitulating the entire process of human IPMN initiation and progression., has become a key breakthrough driving research in this field. Driven by this urgent need, relevant institutions and enterprises both domestically and internationally are continuously innovating, providing unprecedentedly powerful tools for in-depth exploration of the biological mechanisms and translational applications of IPMN.

In the international market,The Jackson Laboratory (JAX)Maintain and commercially distribute proprietary materials with strictly quality-controlled genetic backgroundsJAX® Mouse Strains, its repository contains over 13,000 strains, serving more than 2,400 research institutions, universities, and pharmaceutical companies across 68 countries worldwide. Among these, the immunodeficient mouse strains developed for cancer research (such as NSG™ mice) represent the industry-standard platform for establishing patient-derived xenograft (PDX) models and humanized mouse models. These models are widely used to simulate human tumor growth in vivo and to evaluate the efficacy of immunotherapies.

Its operational mechanism lies in the deep integration of profound genetics research with modern genetic engineering technologies. For instance, its next-generation Atlas™ transgenic mouse platform utilizes precise gene knock-in technology to enable mice to produce fully human antibody sequences, thereby providing a powerful and efficient “in vivo screening” tool for antibody drug discovery and optimization. This effectively addresses issues such as the high immunogenicity of antibodies generated by traditional methods. Furthermore, JAX offers more than just mouse models; through its preclinical services division, it provides pharmaceutical companies with one-stop solutions ranging from model construction, pharmacodynamic evaluation, and pharmacokinetic studies to safety assessment. These studies are conducted during the preclinical stage of drug development, with the core objective of providing critical efficacy and safety data support for candidate drugs to enter human clinical trials (IND filing).

In China,Jiangsu Jicui Yaokang Biotechnology Co., Ltd.Established a globally leading resource library of genetically engineered mouse models. Through its renowned“Spotted Mouse Project”Through such projects, the company has cumulatively developed nearly 30,000 commercialized mouse model strains with independent intellectual property rights, placing its resource volume among the world’s leading positions. These models cover multiple key research areas, including oncology, metabolism, cardiovascular diseases, autoimmune disorders, neurodegenerative diseases, and rare diseases, and can faithfully recapitulate the physiological and pathological features of human diseases.

Its key focus is to support new drug development.Drug Evaluation Models and Preclinical Screening ModelsSpecifically, this refers to leveraging these highly customized or humanized mouse models to evaluate drug efficacy, safety, and mechanisms of action prior to entering human clinical trials. The core mechanism involves using precise gene editing techniques (such as CRISPR/Cas9) to introduce specific human disease-associated gene mutations or enable the expression of human drug target proteins in mice, thereby creating “surrogates” that can simulate human diseases and elicit drug responses similar to those in humans. For example, the humanized mouse models developed by the company, which involve replacing mouse genes with their human counterparts, can more accurately predict drug efficacy and toxicity in humans.

This work is in the preclinical research stage of the new drug development process. To date, GemPharmatech’s technologies and services have supported over 300 Investigational New Drug (IND) applications, serving numerous research institutions, hospitals, and pharmaceutical companies worldwide.

Looking ahead, competition within the industry will increasingly center on the capacity to accurately model complex human diseases, with gene-engineered animal model platforms at the core. Merely possessing a repository of animal models is no longer sufficient; the key determinants of value will be the ability to deeply understand disease mechanisms, design models that more closely mimic clinical pathological features, and efficiently integrate these models into the decision-making chain of new drug development. From a technological evolution perspective, model development is shifting from constructing single-disease phenotypes to dynamically studying tumor–microenvironment interactions within an intact immune system. Accordingly, application scenarios are expanding from basic mechanistic exploration to earlier stages, including target validation and translational medicine research.

This trend implies that demand for models with clear disease specificity and comprehensive pathological progression, such as KPPS, will grow. However, achieving standardized and scalable model deployment, while accumulating reliable data to demonstrate their predictive capability for clinical efficacy, remains a technical and commercialization challenge that the entire industry must collectively address.

* Patent transaction information provided by CSTIP